MURAL - Maynooth University Research Archive Library



    Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus


    Hogan, Andrew and Gaoatswe, Gadintshware and Lynch, Lydia and Corrigan, Michelle and Woods, Conor and O'Connell, Jean and O'Shea, Donal (2014) Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus. Diabetologia, 57. pp. 781-784. ISSN 0012-186X

    [img]
    Preview
    Download (155kB) | Preview


    Share your research

    Twitter Facebook LinkedIn GooglePlus Email more...



    Add this article to your Mendeley library


    Abstract

    Aims/hypothesis Glucagon-like peptide 1 (GLP-1) is a gut hormone used in the treatment of type 2 diabetes mellitus. There is emerging evidence that GLP-1 has anti-inflammatory activity in humans, with murine studies suggesting an effect on macrophage polarisation. We hypothesised that GLP-1 analogue therapy in individuals with type 2 diabetes mellitus would affect the inflammatory macrophage molecule soluble CD163 (sCD163) and adipocytokine profile. Methods We studied ten obese type 2 diabetes mellitus patients starting GLP-1 analogue therapy at a hospital-based diabetes service. We investigated levels of sCD163, TNF-α, IL-1β, IL-6, adiponectin and leptin by ELISA, before and after 8 weeks of GLP-1 analogue therapy. Results GLP-1 analogue therapy reduced levels of the inflammatory macrophage activation molecule sCD163 (220 ng/ml vs 171 ng/ml, p <0.001). This occurred independent of changes in body weight, fructosamine and HbA1c. GLP-1 analogue therapy was associated with a decrease in levels of the inflammatory cytokines TNF-α (264 vs 149 pg/ml, p <0.05), IL-1β (2,919 vs 748 pg/ml, p <0.05) and IL-6 (1,379 vs 461 pg/ml p <0.05) and an increase in levels of the anti-inflammatory adipokine adiponectin (4,480 vs 6,290 pg/ml, p <0.002). Conclusions/interpretation In individuals with type 2 diabetes mellitus, GLP-1 analogue therapy reduces the frequency of inflammatory macrophages. This effect is not dependent on the glycaemic or body weight effects of GLP-1.

    Item Type: Article
    Keywords: GLP-1; Inflammation; Macrophage; Obesity;
    Academic Unit: Faculty of Science and Engineering > Biology
    Item ID: 12428
    Identification Number: https://doi.org/10.1007/s00125-013-3145-0
    Depositing User: Andrew Hogan
    Date Deposited: 17 Feb 2020 15:17
    Journal or Publication Title: Diabetologia
    Publisher: Springer Verlag
    Refereed: Yes
    URI:

    Repository Staff Only(login required)

    View Item Item control page

    Downloads

    Downloads per month over past year